Glaukos Corporation

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Glaukos Corporation sits in the top decile of US sponsors by registered trial count (#500 of 15,742 sponsors by registered trial count).

33 total trials 11 currently recruiting 17 completed top decile by trial count

Glaukos Corporation: 33 sponsored US clinical trials, 11 recruiting.

Glaukos Corporation sponsors 33 registered US clinical trials on ClinicalTrials.gov, 11 of them currently recruiting, and 17 completed. 14 of these trials are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Glaucoma Open-Angle, with 4 trials.

Top-decile sponsor footprint

Glaukos Corporation ranks in the top decile of sponsors by registered trial count (#500 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 42/100

17 of 21 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

33 total, page 1 of 1

RECRUITING Phase 4

Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for Keratoconus

NCT07629557

RECRUITING Phase 3

Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

NCT07495852

RECRUITING Phase 2

Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus

NCT07400952

RECRUITING

Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg

NCT07400926

RECRUITING Phase 2

Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis

NCT07400965

RECRUITING Phase 2

Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

NCT07075718

RECRUITING Phase 4

Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone

NCT06848946

RECRUITING Phase 3

Travoprost Intraocular Implant + iStent Infinite vs. iStent Infinite Alone

NCT06066645

RECRUITING NA

Glaukos® iStent Infinite Trabecular Micro-Bypass System in Subjects With Mild to Moderate Primary Open-angle Glaucoma

NCT06057051

RECRUITING Phase 2

A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED

NCT05966493

RECRUITING Phase 1

Safety and Efficacy of Corneal Cross-linking in Subjects With Keratoconus

NCT05314738

ACTIVE NOT RECRUITING NA

iStent Inject New Enrollment Post-Approval Study

NCT04624698

COMPLETED Phase 2

Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Dry Eye Disease

NCT05119920

COMPLETED Phase 2

Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Presbyopia

NCT05124275

COMPLETED Phase 2

Study of Exchange of Travoprost Intraocular Implant

NCT04615403

TERMINATED Phase 2

NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular Injuries

NCT04081103

COMPLETED Phase 3

Clinical Study Comparing Two Models of a Travoprost Intraocular Implant

NCT03868124

COMPLETED Phase 3

Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%

NCT03519386

COMPLETED Phase 3

Study to Evaluate the Safety and Efficacy of Epi-on Corneal Cross-linking in Eyes With Progressive Keratoconus

NCT03442751

COMPLETED Phase 2

Study Comparing Travoprost Intraocular Implants to Timolol Ophthalmic Solution

NCT02754596

TERMINATED NA

Multicenter Investigation of Trabecular Micro-Bypass Stents vs. Laser Trabeculoplasty

NCT02327312

TERMINATED Phase 3

Safety and Efficacy of Corneal Collagen Cross-Linking in Eyes With Keratoconus

NCT01972854

COMPLETED

Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery Postmarket Registry

NCT01841437

TERMINATED Phase 1

Safety and Efficacy of Corneal Collagen Cross-linking Following LASIK for Treatment of Hyperopia and Hyperopic Astigmatism

NCT01893359

COMPLETED

Post-approval Study of The Glaukos® iStent® Trabecular Micro-bypass Stent: Extended Follow-up of the Premarket Cohort

NCT01836042

COMPLETED Phase 3

Safety and Efficacy Study of Corneal Collagen Cross-Linking in Eyes With Keratoconus

NCT01344187

COMPLETED Phase 3

Safety and Efficacy Study of Corneal Collagen Cross-Linking in Eyes With Keratoconus

NCT01643226

COMPLETED NA

Multicenter Study Using Glaukos® Trabecular Micro-Bypass Stent Model GTS400 Using the G2-M-IS Injector System in Conjunction With Cataract Surgery

NCT01461291

COMPLETED NA

Multicenter Investigation of the Glaukos® Suprachoroidal Stent Model G3 In Conjunction With Cataract Surgery

NCT01461278

COMPLETED Phase 3

GTS400 Stent Implantation in Conjunction With Cataract Surgery in Subjects With Open-angle Glaucoma

NCT01052558

COMPLETED Phase 3

Corneal Collagen Cross-Linking for Ectasia (CXL)

NCT00674661

COMPLETED Phase 3

Corneal Collagen Cross-linking for Progressive Keratoconus

NCT00647699

COMPLETED Phase 3

A Study of the Trabecular Micro-bypass Stent in Combination With Cataract Surgery in Subjects With Open Angle Glaucoma

NCT00323284

What is open in the Glaukos Corporation pipeline

11 recruiting of 33 indexed (33% open); 17 completed (52%).

Phase mix: 14 late (III/IV) vs 11 early (I/II) (balanced across stages).

Top condition: Glaucoma Open-Angle (4 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Glaukos Corporation: open-pipeline peers nationwide

Peers matched on 33 registered trials and 33% open enrollment, not the therapeutic-area sidebar.

Glaukos Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 010203040 0%10%20%30%40% Total trials Recruiting share Glaukos CorporationAclaris TherapeuticsAntonios LikourezosBaylor UniversityBecton, Dickinson and CompanyAadi BioscienceAaron CookAbivax S.A.Actuated Medical
Glaukos Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Glaukos Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 33 trials (± recruiting share)

Sponsors near 33% open enrollment (± trial volume)

What to do with this Glaukos Corporation page

33 registered trials is a research-attention snapshot, not an endorsement of Glaukos Corporation or any single study.

  • 11 of Glaukos Corporation's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Glaucoma Open-Angle is the condition Glaukos Corporation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Glaucoma Open-Angle trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Glaukos Corporation pipeline card: 33 registered trials from official public datasets.Report a data error.